FAST (Focused Abbreviated Screening Technique)-MRI Study
Launched by ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · Aug 31, 2020
Trial Information
Current as of July 23, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Hepatocellular carcinoma (HCC) is the fastest growing cause of cancer death in the United States and now kills over 30,000 Americans annually. To reduce the morbidity and mortality caused by this aggressive cancer, current practice guidelines recommend semi-annual abdominal ultrasound in adults with cirrhosis, the leading risk factor for HCC, to detect HCC nodules when they are small and treatable. Unfortunately, US has poor sensitivity for early-stage HCC in cirrhosis, failing to detect treatable cancer in over half of affected patients. Alternatives such as computed tomography (CT) or mag...
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- • Liver cirrhosis of any etiology.
- • 18 years of age and older.
- • Enrolled in screening/surveillance program for HCC.
- • Clinically indicated imaging-based screening for HCC.
- • Willing and able to complete all study procedures within specified time windows.
- • Patient is able to give informed consent for this study.
- • Exclusion Criteria
- • Contra-indications to MRI.
- • Age less than 18 years.
- • Patients with chronic renal failure or inability to tolerate contrast.
- • Inability to undergo MRI due to lack of insurance coverage.
- • Prior negative screening exam less than 5 months prior to enrollment.
- • Prior hepatic resection.
- • Post liver transplantation.
- • Previously treated HCC or other liver neoplasm.
- • Any other condition or factor that in judgment of study investigator may interfere with study completion.
About Icahn School Of Medicine At Mount Sinai
The Icahn School of Medicine at Mount Sinai is a premier academic institution located in New York City, renowned for its commitment to advancing medical research, education, and patient care. As a leading sponsor of clinical trials, the institution leverages its state-of-the-art facilities and multidisciplinary expertise to drive innovative research initiatives aimed at improving health outcomes. With a focus on translational medicine, the Icahn School of Medicine collaborates with a diverse network of researchers, clinicians, and industry partners to explore novel therapies and interventions across a wide range of medical disciplines. Its rigorous scientific approach and dedication to ethical standards position it as a trusted leader in the clinical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Los Angeles, California, United States
New York, New York, United States
Patients applied
Trial Officials
Bachir Taouli
Principal Investigator
Icahn School of Medicine at Mount Sinai
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials